Bio-Genex Laboratories Inc BGNX
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Bio-Genex Laboratories Inc is a United States based company engaged in the business of designing, developing and commercializing molecular pathology systems for cancer diagnosis, prognosis, precession medicine and life science research. Its products include Xmatrx systems, i6000 systems, i500 Plus, EZ-Retriever, IHC primary antibodies, microRNA probes, special stains, and IHC/ISH detection kits, among others. The product areas in which the company focuses on are multiple fully automated molecular pathology workstations, Immunohistochemistry, In-situ hybridization, Fluorescence in-situ hybridization, Multiplex stains, In-situ PCR, and MicroRNA and HPV probe system. The organization has a business presence all around the globe.